Results 121 to 130 of about 716,122 (354)

Chimeric diphtheria toxin–CCL8 cytotoxic peptide for breast cancer management

open access: yesMolecular Oncology, EarlyView.
DTCCL8 is a recombinant fusion toxin that targets cancer cells expressing chemokine receptors. By combining diphtheria toxin with CCL8, DTCCL8 binds to multiple receptors on tumor cells and induces selective cytotoxicity. This strategy enables receptor‐mediated targeting of cancer and may support the development of chemokine‐guided therapeutics ...
Bernardo Chavez   +5 more
wiley   +1 more source

Gastrointestinal stroma tumor of the stomach

open access: yesRevista Electrónica Dr. Zoilo E. Marinello Vidaurreta, 2016
The gastrointestinal stroma tumor is an infrequent type of tumor of mesenchymal origin called sarcoma. It appears in the wall of the digestive lobe, the stomach, the small intestine, the colon, the esophagus and occasionally in the omentum, mesenteric ...
Jaime Landell Cruz   +1 more
doaj  

Physiological antioxidant system and oxidative stress in stomach cancer patients with normal renal and hepatic function [PDF]

open access: yes, 2010
Role of free radicals has been proposed in the pathogenesis of many diseases. Gastric cancer is a common disease worldwide, and leading cause of cancer death in India.
Chandra Mouli, K   +3 more
core   +1 more source

The Cure: Making a game of gene selection for breast cancer survival prediction [PDF]

open access: yes, 2014
Motivation: Molecular signatures for predicting breast cancer prognosis could greatly improve care through personalization of treatment. Computational analyses of genome-wide expression datasets have identified such signatures, but these signatures leave
Good, Benjamin M.   +5 more
core   +4 more sources

Machine learning for identifying liver and pancreas cancers through comprehensive serum glycopeptide spectra analysis: a case‐control study

open access: yesMolecular Oncology, EarlyView.
This study presents a novel AI‐based diagnostic approach—comprehensive serum glycopeptide spectra analysis (CSGSA)—that integrates tumor markers and enriched glycopeptides from serum. Using a neural network model, this method accurately distinguishes liver and pancreatic cancers from healthy individuals.
Motoyuki Kohjima   +6 more
wiley   +1 more source

Clinicopathological Characteristics of Patients with Gastric Cancer according to the Expression of LIN28A

open access: yesGut and Liver, 2016
Background/AimsAlthough LIN28A is known to potentially play a role in the oncogenesis of various cancers, whether LIN28A expression is a predictor of poor prognosis in patients with gastric cancer has not been fully explored.
Chan Hyuk Park   +4 more
doaj   +1 more source

Acupuncture for cancer pain in adults. [PDF]

open access: yes, 2011
BACKGROUND: Forty percent of individuals with early or intermediate stage cancer and 90% with advanced cancer have moderate to severe pain and up to 70% of patients with cancer pain do not receive adequate pain relief.
Akhileswaran   +70 more
core   +1 more source

β‐TrCP overexpression enhances cisplatin sensitivity by depleting BRCA1

open access: yesMolecular Oncology, EarlyView.
Low levels of β‐TrCP (Panel A) allow the accumulation of BRCA1 and CtIP, which facilitate the repair of cisplatin‐induced DNA damage via homologous recombination (HR) and promote tumor cell survival. In contrast, high β‐TrCP expression (Panel B) leads to BRCA1 and CtIP degradation, impairing HR repair, resulting in persistent DNA damage and apoptosis ...
Rocío Jiménez‐Guerrero   +8 more
wiley   +1 more source

Revisiting the mortality of France and Italy with the multiple-cause-of-death approach [PDF]

open access: yes
In this paper, we use the multiple cause-of-death approach to compare the mortality profiles of France and Italy in 2003. Our analysis leads to a substantial re-evaluation of the role played by certain conditions in the process leading to death ...
Aline Desesquelles   +6 more
core  

Olaparib synergy screen reveals Exemestane induces replication stress in triple‐negative breast cancer

open access: yesMolecular Oncology, EarlyView.
Screening 166 FDA‐approved anticancer drugs identifies the aromatase inhibitor Exemestane as a synergistic partner of PARP inhibitor Olaparib in BRCA‐proficient triple‐negative breast cancer. Exemestane induces ROS‐mediated replication stress, enhancing DNA damage and apoptosis alongside Olaparib.
Nur Aininie Yusoh   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy